Nkx3-1-IRES-CreERT2

Nomenclature

C57BL/6Smoc-Nkx3-1em1(IRES-CreERT2)Smoc

Cat. NO.

NM-KI-200071

Strain State

Sperm cryopreservation

Export PDF

Gene Summary

Gene Symbol
Nkx3-1

Synonyms

Bax; NKX3A; NKX3.1; Nkx-3.1; bagpipe

Chromosome

14

NCBI ID

18095

MGI ID

97352

Ensembl ID

ENSMUSG00000022061

Pubmed

Nkx3-1

Human Ortholog

NKX3-1

Model Description

A IRES-CreERT2 expression cassette was knocked into the Nkx3-1 gene stop codon site.
Research Application：This gene encodes a homeobox-containing transcription factor. This transcription factor functions as a negative regulator of epithelial cell growth in prostate tissue. This strain is useful in studying prostate.

Validation Data

image.png

Fig. 1 CreERT2-mediated recombination in the prostate of Nkx3-1CreERT2/+; Rosa26tdTomato/+ mouse. TdTomato(red) expression can be detected in the prostate lumen cells of Nkx3-1CreERT2/+; Rosa26tdTomato/+ mouse after tamoxifen treatment. 

image.png

Fig. 2 Detection of tdTomato(red) in various tissues of Nkx3-1CreERT2/+; Rosa26tdTomato/+ mice after tamoxifen treatment. Tdtomato was expressed in the prostate and individual cells of kidney. TdTomato can not be detected in the brain, thymus, retina, lung, liver, stomach, salivary gland, pancreas, colon, intestine, spleen, skin, testis and epididymis. (For more detailed information please contact our technical advisor.)


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more